Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Maintains Buy on CytomX Therapeutics, Lowers Price Target to $8

BTIG Maintains Buy on CytomX Therapeutics, Lowers Price Target to $8

BTIG analyst Kaveri Pohlman maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $16 to $8.

July 7, 2022

1 minute read

BTIG analyst Kaveri Pohlman maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $16 to $8.

Evercore ISI Group Maintains Outperform Rating for Sherwin-Williams: Here’s What You Need To Know

September 8, 1:00 PM

Evercore ISI Group has decided to maintain its Outperform rating of Sherwin-Williams (NYSE:SHW) and raise its price target…

July 14, 12:04 PM

-Reuters

November 15, 12:11 AM

Tesla's initial resell clause prevented Cybertruck owners from selling their vehicles within the first year following delivery.

July 31, 1:00 PM

Truist Securities has decided to maintain its Hold rating of Weyerhaeuser (NYSE:WY) and raise its price target from…